GSK'227 breakthrough designation for relapsed/refractory osteosarcoma
- Sponsor
- GSK plc $GSK
- Indication
- relapsed or refractory osteosarcoma
FDA granted Breakthrough Therapy Designation to GSK'227 (a B7-H3-targeted antibody-drug conjugate) for the treatment of relapsed or refractory osteosarcoma. Based on ARTEMIS-002 Phase 2 data.
What this means
Osteosarcoma is the most common bone cancer in teenagers and young adults, and patients whose disease returns after initial treatment have very few options. GSK'227 is an antibody-drug conjugate: an antibody that finds a specific tumor marker called B7-H3 and delivers a cancer-killing payload directly to those cells. FDA's Breakthrough Therapy Designation is reserved for drugs targeting serious conditions where early evidence suggests meaningful improvement over existing options; it opens up more frequent FDA interactions and can shorten the path to approval. The designation is based on the ARTEMIS-002 Phase 2 trial, which showed a 20% objective response rate in patients with relapsed or refractory osteosarcoma.